Study study type PathologyT1T0Patientssample sizesROB Results

mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population

versus placebo
nivolumab alone
ATTRACTION-2 (Kang), 2017
  NCT02267343
RCTmGC or mGEJC - L2 - all populationnivolumabplacebopatients with advanced gastric or gastro-oesophageal junction cancer who had been previously been treated with two or more chemotherapy regimens330 / 163low
inconclusive
  • suggested 37 % decrease in deaths (OS) (PE)
  • suggested 38 % decrease in deaths (OS) (extension)
  • suggested 40 % decrease in PFS (extension)
  • suggested 40 % decrease in progression or deaths (PFS)